Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative...

Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma ( Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA )

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high...

Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill - Cleveland Clinic, Cleveland, USA

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

Prof Elizabeth Budde - City of Hope, Duarte, USA

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )

Study indicates circulating tumour cell assessment should be part of multiple...

Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain

Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup ( Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain )

Initial treatment options for relapsed/refractory multiple myeloma patients

Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...

$Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )$

ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R...

Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...

ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L...

Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora...

Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )

Post-HSCT management of ALL - Adult ALL perspective

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Post-HSCT management of ALL - Adult ALL perspective ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Safety profile of BiTE therapy

Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany

More from ecancer